Sacral neuromodulation versus personalized conservative treatment in patients with idiopathic slow-transit constipation: study protocol of the No.2-trial, a multicenter open-label randomized controlled trial and cost-effectiveness analysis

Heemskerk, SCMRotteveel, AHBenninga, MABaeten, CIMMasclee, AAMMelenhorst, Jvan Kuijk, SMJDirksen, CDBreukink, SO2018-02-272018-02-272018-02-22Sacral neuromodulation versus personalized conservative treatment in patients with idiopathic slow-transit constipation: study protocol of the No.2-trial, a multicenter open-label randomized controlled trial and cost-effectiveness analysis. 2018 Int J Colorectal Dis1432-12622947073110.1007/s00384-018-2978-xhttp://hdl.handle.net/10029/621458The evidence regarding the (cost-)effectiveness of sacral neuromodulation (SNM) in patients with therapy-resistant idiopathic slow-transit constipation is of suboptimal quality. The Dutch Ministry of Health, Welfare and Sports has granted conditional reimbursement for SNM treatment. The objective is to assess the effectiveness, cost-effectiveness, and budget impact of SNM compared to personalized conservative treatment (PCT) in patients with idiopathic slow-transit constipation refractory to conservative treatment.enArchived with thanks to International journal of colorectal diseaseSacral neuromodulation versus personalized conservative treatment in patients with idiopathic slow-transit constipation: study protocol of the No.2-trial, a multicenter open-label randomized controlled trial and cost-effectiveness analysisArticleInt J Colorectal Dis 2018; 33(4):493-501